AMYLYX PHARMACEUTICALS INC
AMLXNASDAQTrading Snapshot
- Day Range
- $284.80 – $289.44
- 52-Week Range
- —
- Volume
- $3.84B
- Avg Volume
- $2.60B
- Shares Outstanding
- —
- Next Earnings
- Sep 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $45.66B
- Last Q Revenue
- $12.52B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own AMLX
- ✓High-growth profile — revenue up -0.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About AMYLYX PHARMACEUTICALS INC
A company profile for AMYLYX PHARMACEUTICALS INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild
Amylyx shifts to endocrine with avexitide in Phase 3 LUCIDITY for post-bariatric hypoglycemia; cash runway to 2028. Click here to read more.
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsLindsey Allen - Head of Investor Relations &...
Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms
Amylyx Pharma (AMLX) Q2 loss misses, stock dips; investors await LUCIDITY trial data on avexitide expected late Aug/early Sep.
RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028
Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 15.22 percent increase over losses of $(0.46) per share from
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $20 to $26.
SpaceX's First Earnings Post IPO
Wall Street Week Ahead: key earnings (SpaceX, AMD), IPOs, dividends & macro data (PMIs, jobs). Read here for more details.